Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Bought by Vestal Point Capital LP

Vestal Point Capital LP grew its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 31.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,725,000 shares of the company's stock after acquiring an additional 410,000 shares during the quarter. Vestal Point Capital LP owned about 2.44% of Ventyx Biosciences worth $3,760,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Palumbo Wealth Management LLC bought a new stake in Ventyx Biosciences during the 3rd quarter valued at about $26,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock worth $30,000 after buying an additional 5,310 shares during the period. SG Americas Securities LLC bought a new position in shares of Ventyx Biosciences during the 2nd quarter worth $32,000. Intech Investment Management LLC purchased a new position in shares of Ventyx Biosciences during the third quarter valued at $42,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock valued at $56,000 after acquiring an additional 7,096 shares in the last quarter. 97.88% of the stock is owned by hedge funds and other institutional investors.

Ventyx Biosciences Trading Up 1.1 %

Shares of VTYX stock traded up $0.03 during trading hours on Friday, reaching $2.68. 731,098 shares of the company's stock were exchanged, compared to its average volume of 2,052,684. Ventyx Biosciences, Inc. has a 1 year low of $1.67 and a 1 year high of $11.48. The stock has a market cap of $189.50 million, a PE ratio of -1.12 and a beta of 0.37. The stock's fifty day moving average price is $2.20 and its two-hundred day moving average price is $2.62.

Insider Buying and Selling

In other news, CEO Raju Mohan acquired 261,752 shares of Ventyx Biosciences stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $2.01 per share, for a total transaction of $526,121.52. Following the completion of the purchase, the chief executive officer now directly owns 2,175,028 shares in the company, valued at $4,371,806.28. This trade represents a 13.68 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 18.18% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on VTYX shares. Canaccord Genuity Group reduced their price target on shares of Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating for the company in a report on Monday, August 12th. HC Wainwright restated a "neutral" rating and set a $6.00 target price on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reissued an "outperform" rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. Finally, Wells Fargo & Company dropped their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating on the stock in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.